$ORN News

Orion Group: Q3 Could Go Well, But What Matters Is The 2027 Guidance

JP Morgan Maintains Overweight on Orion Group Holdings, Lowers Price Target to $14

Orion Group Holdings to Report Third Quarter 2026 Financial Results on Tuesday, October 27, 2026

ORYZON Receives European Medicines Agency Approval to Initiate the HOPE-2 Phase II Study of Vafidemstat for the Treatment of Phelan-McDermid Syndrome (PMS)

Orion Group Holdings Announces Conference Participation

ORYZON to Participate in Upcoming Events in September and October

ORYZON Announces Notice of Allowance for U.S. Patent Application Covering Iadademstat Combination With Gilteritinib

Orion Group Holdings (ORN) Price Target Decreased by 15.36% to 14.89

ORN Q2 Earnings Call Ties Profit Reset to Marine Delays

ORN: Marine Setback Is Noise, Not Signal - Reiterating Strong Buy

Orion Group Holdings: Rising Costs And Client Delays Have Me Worried

Orion Group Q2 Earnings Call Highlights

Orion Group Holdings Inc (ORN) Q2 2026 Earnings Call Highlights: Navigating Challenges with ...

Orion Group Holdings, Inc. (ORN) Q2 2026 Earnings Call Transcript

Orion Group Holdings, Inc. Q2 2026 Earnings Call Summary

Orion Group Holdings, Inc. 2026 Q2 - Results - Earnings Call Presentation

Orion Marine (ORN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Orion Group Holdings (NYSE:ORN) Reports Q2 Miss and Cuts Full-Year Guidance, Stock Plunges

Orion Group Holdings Reports Second Quarter 2026 Results

Orion Group Holdings Lowers FY2026 Adj EPS Guidance from $0.36-$0.42 to $0.23-$0.30 vs $0.39 Est; Affirms FY2026 Sales Guidance of $900.000M-$950.000M vs $938.739M Est